



ANALYTICA LTD - ABN 12 006 464 866

ASX ANNOUNCEMENT

Invitation to Investment Seminars

17 July 2015: Analytica Ltd (ASX: ALT), developer of the PeriCoach® System for women who suffer Stress Urinary Incontinence, is pleased to invite shareholders and interested investors to a series of Analytica company briefings. Analytica's Directors and CEO will present on latest news and fund raising and be available for discussion and to answer questions.

Event details:

City	Date and Time	Venue	Hosts
Brisbane	Wednesday 22 July 2015 5.30 for 6pm start	Katana Room, Level 2, 320 Adelaide Street Brisbane QLD 4000	Geoff Daly (CEO) Warren Brooks (Non-Executive Director)
Melbourne	Thursday 23 July 2015 5.30 for 6pm start	Monsoon Auditorium, Level 12, 15 William Street Melbourne VIC 3000	Geoff Daly (CEO)
Perth	Friday 24 July 2015 2.30 for 3pm start	Duxton 3 Room, Duxton Hotel 1 St Georges Terrace Perth WA 6000	Ross Mangelsdorf (Executive Director & CFO)
Sunshine Coast	Monday 27 July 2015 5.30 for 6pm start	Plantation 3 Room, Noosa Springs Links Road, Sunshine Coast Noosa Heads QLD 4567	Dr Michael Monsour (Chairman) Ross Mangelsdorf (Executive Director & CFO)
Sydney	Tuesday 28 July 2015 5.30 for 6pm start	Canberra Room The Menzies 14 Carrington Street Sydney NSW 2000	Carl Stubbings (Non-Executive Director) Geoff Daly (CEO)

To assist with logistics and catering, it would be most appreciated if you could RSVP to <u>info@monsoon.com.au</u>, or call Monsoon Communications on 03 9620 3333, at least 2 business days prior to the events, specifying which venue you wish to attend.

We look forward to seeing you there and appreciate your continued support.

Geoff Daly

Chief Executive Officer

GPO Box 670 Brisbane 4001 QLD Australia | t +61 7 3278 1950



For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark clearance. The product has USFDA 510(k) clearance. The product has been on sale in Australia and New Zealand since January, and recently launched in the UK and Ireland, and in the USA. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence.



www.analyticamedical.com